Tuesday, July 16, 2024
Home Stock Analysis Everything you need to know about OS Therapies’ upcoming IPO

Everything you need to know about OS Therapies’ upcoming IPO

by xyonent
0 comment
Ipo 1.jpg

IPO activity has increased significantly this year compared to 2023, when the market slowed. The first half of the year saw a double-digit increase in IPOs, led by the technology and biotechnology sectors. Recently, OS Therapies Incorporated, a clinical-stage biopharmaceutical company focused on developing treatments for osteosarcoma, filed an application to go public with the Securities and Exchange Commission.


The company plans to offer approximately 2 million shares of its common stock in its initial public offering at an expected price of $4.00 per share. The company applied to list on the NYSE American and began trading under the ticker symbol. OSX. The offering is being underwritten by Brookline Capital Markets, a division of Arcadia Securities. The underwriters have been granted an option to purchase up to an additional 300,000 shares, exercisable for 45 days.

The company seeks to raise approximately $6.74 million from the offering, or $7.84 million if the underwriters fully exercise their option to purchase additional shares. Approximately $4.2 million of the proceeds will be used to advance the clinical development of its lead product candidate, OST-HER2, for osteosarcoma. The company plans to use approximately $1.2 million to advance the development of its ovarian cancer treatment, OST-tADC.

The remaining net proceeds will be used for the discovery and development of new product candidates, working capital, and other general corporate purposes. The Company does not currently intend to pay cash dividends to its stockholders and intends to retain all available funds and future earnings to fund the growth and development of its business.


OS Therapies was founded in April 2018 by Paul Romness, who has since served as its President and Chief Executive Officer. For the three months ended March 2024, the company reported a net loss attributable to shareholders of $1.49 million, or $0.25 per share. This compares to a loss of $1.88 million, or $0.35 per share, in the same period a year ago.Research and development expenses were $360,000 for the three month period, down from $750,000 in the same period last year.

You may also like

Leave a Comment

About Us


At InvestXyon, we empower individuals with knowledge for informed investing, financial navigation, and secure futures. Our trusted platform covers investments, stocks, personal finance, retirement, and more.

Feature Posts


Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!